筛选美国国立癌症研究所-药物研发技术平台（NCI-DTP）文库以鉴定针对伯氏疏螺旋体的新型候选药物。 - Suppr

Screening of NCI-DTP library to identify new drug candidates for Borrelia burgdorferi.

作者信息

Pothineni Venkata Raveendra, Wagh Dhananjay, Babar Mustafeez Mujtaba, Inayathullah Mohammed, Watts R Edward, Kim Kwang-Min, Parekh Mansi B, Gurjarpadhye Abhijit Achyut, Solow-Cordero David, Tayebi Lobat, Rajadas Jayakumar

机构信息

Biomaterials and Advanced Drug Delivery & Stanford Cardiovascular Pharmacology Division, Cardiovascular Institute, Stanford University, School of Medicine, Palo Alto, CA, USA.

Chemical & Systems Biology, Stanford University School of Medicine, Stanford, CA, USA.

出版信息

J Antibiot (Tokyo). 2017 Mar;70(3):308-312. doi: 10.1038/ja.2016.131. Epub 2016 Nov 9.

DOI:10.1038/ja.2016.131

PMID:27826144

Abstract

摘要

相似文献

Screening of NCI-DTP library to identify new drug candidates for Borrelia burgdorferi.

J Antibiot (Tokyo). 2017 Mar;70(3):308-312. doi: 10.1038/ja.2016.131. Epub 2016 Nov 9.

Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening.

Drug Des Devel Ther. 2016 Apr 1;10:1307-22. doi: 10.2147/DDDT.S101486. eCollection 2016.

Identification of new compounds with high activity against stationary phase Borrelia burgdorferi from the NCI compound collection.

Emerg Microbes Infect. 2015 Jun 3;4(6):e31. doi: 10.1038/emi.2015.31.

Erythromycin resistance in Borrelia burgdorferi.

Antimicrob Agents Chemother. 2002 Nov;46(11):3637-40. doi: 10.1128/AAC.46.11.3637-3640.2002.

In vitro activity of tigecycline against multiple strains of Borrelia burgdorferi.

J Antimicrob Chemother. 2009 Apr;63(4):709-12. doi: 10.1093/jac/dkn551. Epub 2009 Jan 31.

In vitro susceptibility of Borrelia burgdorferi isolates to three antibiotics commonly used for treating equine Lyme disease.

BMC Vet Res. 2017 Sep 29;13(1):293. doi: 10.1186/s12917-017-1212-3.

Persister Development by Borrelia burgdorferi Populations In Vitro.

Antimicrob Agents Chemother. 2015 Oct;59(10):6288-95. doi: 10.1128/AAC.00883-15. Epub 2015 Jul 27.

In vitro susceptibility of isolates of Borrelia burgdorferi s.l. to antimicrobial agents.

Int J Immunopathol Pharmacol. 2006 Jul-Sep;19(3):545-9. doi: 10.1177/039463200601900310.

Assessment of methylthioadenosine/S-adenosylhomocysteine nucleosidases of Borrelia burgdorferi as targets for novel antimicrobials using a novel high-throughput method.

J Antimicrob Chemother. 2009 Jun;63(6):1163-72. doi: 10.1093/jac/dkp129. Epub 2009 Apr 17.

Establishment and validation of a 384-well antibacterial assay amenable for high-throughput screening and combination testing.

J Microbiol Methods. 2015 Nov;118:173-5. doi: 10.1016/j.mimet.2015.09.019. Epub 2015 Oct 1.

引用本文的文献

A high-resolution screen identifies a preexisting beta-lactam that specifically treats Lyme disease in mice.

Sci Transl Med. 2025 Apr 23;17(795):eadr9091. doi: 10.1126/scitranslmed.adr9091.

Combining Double-Dose and High-Dose Pulsed Dapsone Combination Therapy for Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome and Co-Infections, Including Bartonella: A Report of 3 Cases and a Literature Review.

Microorganisms. 2024 Apr 30;12(5):909. doi: 10.3390/microorganisms12050909.

ABDpred: Prediction of active antimicrobial compounds using supervised machine learning techniques.

Indian J Med Res. 2024 Jan 1;159(1):78-90. doi: 10.4103/ijmr.ijmr_1832_22. Epub 2024 Mar 4.

Comparison of the Efficacy of Longer versus Shorter Pulsed High Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post Treatment Lyme Disease Syndrome with Bartonellosis and Associated Coinfections.

Microorganisms. 2023 Sep 12;11(9):2301. doi: 10.3390/microorganisms11092301.

Efficacy of Short-Term High Dose Pulsed Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-Infections: A Report of Three Cases and Literature Review.

Antibiotics (Basel). 2022 Jul 7;11(7):912. doi: 10.3390/antibiotics11070912.

A human secretome library screen reveals a role for Peptidoglycan Recognition Protein 1 in Lyme borreliosis.

PLoS Pathog. 2020 Nov 11;16(11):e1009030. doi: 10.1371/journal.ppat.1009030. eCollection 2020 Nov.

Efficacy of Double-Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-infections: A Report of Three Cases and Retrospective Chart Review.

Antibiotics (Basel). 2020 Oct 22;9(11):725. doi: 10.3390/antibiotics9110725.

Repurposing Disulfiram (Tetraethylthiuram Disulfide) as a Potential Drug Candidate against In Vitro and In Vivo.

Antibiotics (Basel). 2020 Sep 22;9(9):633. doi: 10.3390/antibiotics9090633.

Murine Skin Model for Biofilm.

Antibiotics (Basel). 2020 Aug 19;9(9):528. doi: 10.3390/antibiotics9090528.

Azlocillin can be the potential drug candidate against drug-tolerant Borrelia burgdorferi sensu stricto JLB31.

Sci Rep. 2020 Mar 2;10(1):3798. doi: 10.1038/s41598-020-59600-4.

本文引用的文献

Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening.

Drug Des Devel Ther. 2016 Apr 1;10:1307-22. doi: 10.2147/DDDT.S101486. eCollection 2016.

Identification of Additional Anti-Persister Activity against Borrelia burgdorferi from an FDA Drug Library.

Antibiotics (Basel). 2015 Sep 16;4(3):397-410. doi: 10.3390/antibiotics4030397.

Identification of new compounds with high activity against stationary phase Borrelia burgdorferi from the NCI compound collection.

Emerg Microbes Infect. 2015 Jun 3;4(6):e31. doi: 10.1038/emi.2015.31.

Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library.

Emerg Microbes Infect. 2014 Jul;3(7):e49. doi: 10.1038/emi.2014.53. Epub 2014 Jul 2.

Borrelia burgdorferi, the Causative Agent of Lyme Disease, Forms Drug-Tolerant Persister Cells.

Antimicrob Agents Chemother. 2015 Aug;59(8):4616-24. doi: 10.1128/AAC.00864-15. Epub 2015 May 26.

Borreliacidal activity of Borrelia metal transporter A (BmtA) binding small molecules by manganese transport inhibition.

Drug Des Devel Ther. 2015 Feb 11;9:805-16. doi: 10.2147/DDDT.S77063. eCollection 2015.

Lyme disease: diagnostic issues and controversies.

Expert Rev Mol Diagn. 2015 Jan;15(1):1-4. doi: 10.1586/14737159.2015.989837. Epub 2014 Dec 8.

Lyme disease: a rigorous review of diagnostic criteria and treatment.

J Autoimmun. 2015 Feb;57:82-115. doi: 10.1016/j.jaut.2014.09.004. Epub 2014 Oct 16.

Lyme disease testing by large commercial laboratories in the United States.

Clin Infect Dis. 2014 Sep 1;59(5):676-81. doi: 10.1093/cid/ciu397. Epub 2014 May 30.

Xenodiagnosis for posttreatment Lyme disease syndrome: resolving the conundrum or adding to it?

Clin Infect Dis. 2014 Apr;58(7):946-8. doi: 10.1093/cid/cit942. Epub 2014 Feb 11.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Screening of NCI-DTP library to identify new drug candidates for Borrelia burgdorferi.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献